GDC 0810

Drug Profile

GDC 0810

Alternative Names: ARN 810; GDC-0810; RG 6046; RO-7056118

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aragon Pharmaceuticals
  • Developer Genentech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 27 Apr 2017 Discontinued - Phase-I for Breast cancer (In the elderly, In volunteers, In adults) in United Kingdom (PO), because the company intends to pursue another candidate for further development (Genentech email communication) (Roche pipeline, June 2017)
  • 27 Apr 2017 Discontinued - Phase-I for Breast cancer (In volunteers) in USA (PO), because the company intends to pursue another candidate for further development (Genentech email communication) (Roche pipeline, June 2017)
  • 27 Apr 2017 Discontinued - Phase-II for Breast cancer (Locally recurrent, Metastatic disease) in USA, Netherlands, Spain, Germany (PO), because the company intends to pursue another candidate for further development (Genentech email communication) (Roche pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top